Announcements
- Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
- Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
- Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
- Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
- Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
- Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
- Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
More ▼
Key statistics
As of last trade Minerva Neurosciences Inc (4MNA:FRA) traded at 2.24, 7.69% above its 52-week low of 2.08, set on May 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.24 |
---|---|
High | 2.24 |
Low | 2.24 |
Bid | 2.16 |
Offer | 2.40 |
Previous close | 2.24 |
Average volume | 55.56 |
---|---|
Shares outstanding | 6.99m |
Free float | 5.44m |
P/E (TTM) | -- |
Market cap | 17.55m USD |
EPS (TTM) | -4.48 USD |
Data delayed at least 15 minutes, as of May 10 2024 08:24 BST.
More ▼